2013;8(9):277.
insignificant increase in mean EF and LVDD after 8 weeks and six months regarding baseline. Within the groups there was a significant decrease in mean NT-proBNP. Within ramipril group, the mean NT-proBNP decreased significantly after 8 weeks (205±180.8 pmol/l vs 67.0±66.9 pmol/l, p<0.01) and six months (205.0±180.8 pmol/l vs 33.1±27.9 pmol/l, p<0.001) regarding the baseline levels. Within losartan group, NT-proBNP also decreased significantly after 8 weeks (237.4±203.5 pmol/l vs 89.2±101.2 pmol/l, p<0.01) and six months (237.4±203.5 pmol/l vs 52.3±76.8 pmol/l, p<0.001).
Conclusion:
In nearly 50% of our asymptomatic (Killip classes I-II) STEMI patients after PPCI NT-proBNP was increased >200 pmol/l. The efficacy of losartan was equal to ramipril in reducing NT-proBNP and increasing EF 8 weeks and six months after randomization suggesting that they equally prevent heart failure and systolic dysfunction in STEMI patients, treated by PPCI.
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Ramipril and losartan are equal in preventing left ventricular systolic dysfunction in ST-elevation myocardial infarction patients treated by primary percutaneous coronary intervention
